Improvement seen in fetal survival following preeclampsia

September 19, 2006

Fetal survival following a preeclamptic pregnancy has improved substantially over the last 35 years in Norway, likely due to a reduction in stillbirths and improvements in clinical management, according to a study in the September 20 issue of JAMA.

Preeclampsia (a potentially dangerous condition that may develop in late pregnancy with symptoms that include high blood pressure, fluid retention, excessive weight gain, and the presence of protein in the urine) is a well-known cause of perinatal (occurring during the period around birth) death. Despite improvements in clinical management, preeclampsia often culminates in the delivery of a very preterm infant following medical intervention. Even mild preterm delivery substantially increases the risk of neonatal death. Preeclampsia can progress rapidly, putting both mother and child at severe risk if no action is taken. Medically indicated preterm delivery may help prevent stillbirth. This practice has increased in recent decades, but its net effect on fetal and infant survival has not been assessed.

Olga Basso, Ph.D., of the National Institute of Environmental Health Sciences, Research Triangle Park, N.C., and colleagues examined changes over time in perinatal and early childhood survival in relation to preeclampsia in Norway. The study included data from 804,448 first-born infants with Norwegian-born mothers and registered in the Medical Birth Registry of Norway between 1967 and 2003, including 770,613 pregnancies without preeclampsia and 33,835 pregnancies with preeclampsia.

The researchers found that among preeclamptic pregnancies, inductions before 37 weeks (of gestation) increased from 8 percent in 1967-1978 to nearly 20 percent in 1991-2003. In 1967-1978, more than 25 percent of all infants born before 34 completed weeks died in the neonatal period, as opposed to 5 percent in 1991-2003.

" ... preeclampsia was an important cause of fetal death in Norway during the late 1960s and throughout the 1970s, but its impact has waned. While risk of stillbirth was 4.2 times higher with preeclampsia, it is now only 1.3 times higher. Preeclampsia still carries a 2-fold increased risk of neonatal death, which has changed little over time. This stability in neonatal risk is remarkable, considering the increasing number of very preterm deliveries in recent years resulting from aggressive obstetric management of preeclampsia. Modern medical management of preeclampsia appears to have been effective in preventing fetal death without causing an increase in infant or maternal death," the authors conclude.
-end-
(JAMA. 2006;296:1357-1362. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This research was supported in part by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Preeclampsia Articles from Brightsurf:

Brigham researchers make strides in detecting preeclampsia risk
To improve early detection of preeclampsia risks and better classify potential subtypes of the disease, a team led by researchers from Brigham and Women's Hospital analyzed an array of maternal and placental proteins, identifying several biomarkers that, from a blood sample drawn at 12 weeks gestation, can help predict the risk of preeclampsia and, equally importantly, can assess who may develop more severe forms of the condition.

Researchers found a link between genes and preeclampsia
Researchers have showed that HLA-G gene regulates male-to-female ratio at birth.

Novel biomarker discovery could lead to early diagnosis for deadly preeclampsia
Preeclampsia is a dangerous condition that worldwide kills over 70,000 women and 500,000 babies each year.

RNA molecules in maternal blood may predict pregnancies at risk for preeclampsia
UC San Diego researchers have identified small molecules in the blood of asymptomatic pregnant women that may predict risk for preeclampsia, responsible for a significant proportion of maternal and neonatal deaths, low birth weight and is a primary cause of premature birth.

Review assesses stem cell therapy potential for treating preeclampsia
A review of using stem cells to treat preeclampsia, a dangerous condition in pregnancy, indicates that mesenchymal stem/stromal cells (MSCs), or their secreted vesicles, have the potential to be used as therapies that could progress to clinical trials.

Genetic signature may identify mothers at risk for preeclampsia
Researchers at Baylor College of Medicine have identified a genetic signature combining certain maternal and fetal gene variants that are associated with a higher risk of preeclampsia.

Women with preeclampsia may be at greater risk for cardiac conditions later in life
Women who have gestational hypertension or preeclampsia in at least one pregnancy will have higher cardiovascular risk than women without such a history, and that this elevated risk persists at least into their 60s.

Medication use during pregnancy is common in women with preeclampsia
Use of medications during pregnancy is more common in women with preeclampsia than in those without, according to a British Journal of Clinical Pharmacology analysis of women who gave birth at a hospital in Finland in 2002-2016.

Best strategy for managing hypertension and preeclampsia at end of pregnancy
In 2009, the Hypertension and Preeclampsia Intervention Trial At near Term-I (HYPITAT- I) trial showed that inducing labor in women with gestational hypertension or preeclampsia at the end of pregnancy reduces the number of high risk situations for the mother, without compromising the health of newborns.

Narrowing risk of preeclampsia to a specific phenotype
In a recent paper in The Journal of Clinical Endocrinology & Metabolism, MUSC researchers look at preeclampsia when it coincides with type 1 diabetes.

Read More: Preeclampsia News and Preeclampsia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.